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Inhibitory glycinergic neurotransmission is terminated by the speciﬁc glycine transporters GlyT1 and
GlyT2 which actively reuptake glycine from the synaptic cleft. GlyT1 is associated with both glycinergic
and glutamatergic pathways, and is the main regulator of the glycine levels in the synapses. GlyT2 is the
main supplier of glycine for vesicle reﬁlling, a process that is vital to preserve the quantal glycine content
in synaptic vesicles. Therefore, to control glycinergic neurotransmission efﬁciently, GlyT1 and GlyT2
activity must be regulated by diverse neuronal and glial signaling pathways. In this work, we have
investigated the possible functional modulation of GlyT1 and GlyT2 by glycogen synthase kinase 3
(GSK3b). This kinase is involved in mood stabilization, neurodegeneration and plasticity at excitatory and
inhibitory synapses. The co-expression of GSK3b with GlyT1 or GlyT2 in COS-7 cells and Xenopus laevis
oocytes, leads to inhibition and stimulation of GlyT1 and GlyT2 activities, respectively, with a decrease of
GlyT1, and an increase in GlyT2 levels at the plasma membrane. The speciﬁcity of these changes is
supported by the antagonism exerted by a catalytically inactive form of the kinase and through inhibitors
of GSK3b such as lithium chloride and TDZD-8. GSK3b also increases the incorporation of 32Pi into GlyT1
and decreases that of GlyT2. The pharmacological inhibition of the endogenous GSK3b in neuron cultures
of brainstem and spinal cord leads to an opposite modulation of GlyT1 and GlyT2.Our results suggest that
GSK3b is important for stabilizing and/or controlling the expression of functional GlyTs on the neural cell
surface.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Inhibitory glycinergic neurotransmission is terminated by the
speciﬁc glycine transporters GlyTs (GlyT1 and GlyT2) whichyl-4-isoxazolepropionic acid;
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z).actively reuptake glycine from the synaptic cleft. GlyTs belong to
the neurotransmitter: sodium symporter family (SLC6 gene family),
which includes transporters for most of the neurotransmitters,
serotonin, dopamine, norepinephrine and GABA, in the central
nervous system (CNS) (Aragon and Lopez-Corcuera, 2003). GlyT1 is
associatedwith both glycinergic and glutamatergic pathways and is
the main regulator of glycine levels in the synapses. The neuronal
transporter GlyT2 recycles the neurotransmitter to the presynaptic
terminal, a process that is absolutely necessary to preserve the
quantal glycine content inside the synaptic vesicles (Apostolides
and Trussell, 2013; Gomeza et al. 2003b; Harvey and Yee, 2013;
Rousseau et al., 2008). Mouse gene disruption studies have
revealed that constitutive deletion of either GlyT1 or GlyT2 is
lethal (primarily as a result of excessive or deﬁcient glycinergic
inhibition, respectively), and suggest that alterations in GlyTs may
underlie several human disorders (Aragon and Lopez-Corcuera,
2005; Gomeza et al., 2003a, 2003b). These studies revealed the
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nergic and glutamatergic pathways that controls the balance of
neuronal excitation and inhibition within several neural circuits.
GlyT1 and GlyT2 have been related to disorders of central and pe-
ripheral nervous system, such as schizophrenia, depression, epi-
lepsy, obsessive-compulsive disorders, anxiety disorders, pain,
alcohol dependence, breathing disorders and hereditary hyper-
ekplexia (Harvey and Yee, 2013). Indeed, mutations in the gene
encoding GlyT2 are the second main cause of hyperekplexia in
humans (Carta et al., 2012; Eulenburg et al., 2006; Gimenez et al.,
2012; Rees et al., 2006) and produce congenital muscular dysto-
nia type 2 (CMD2) in Belgian Blue cattle (Gill et al., 2012). Moreover
GlyT1 inhibitors may improve cognitive deﬁcits of schizophrenia by
increasing glycine levels around the NMDA receptors. GlyT1 in-
hibitors are being developed by the pharmaceutical industry,
mostly intended for treatment of cortical NMDA receptor hypo-
function in schizophrenia (Javitt, 2008; Pinard et al., 2010).
An analysis of knock-out animals proved that the modulation of
glycine transporter expression and/or transport activity inﬂuenced
glycine-mediated neurotransmission and opened a way to ﬁnd
therapeutic applications (Gomeza et al., 2003a, 2003b). The levels
of active glycine transporters in the plasma membrane are
controlled by several factors in a regulated manner (de Juan-Sanz
et al., 2011; de Juan-Sanz et al., 2013a; de Juan-Sanz et al., 2013b;
Fornes et al., 2008; Geerlings et al., 2001; Nu~nez et al., 2008). In the
CNS these regulatory pathways must be triggered by physiological
stimuli or the activity of appropriate receptors (Jimenez et al.,
2011).
Glycogen synthase kinase 3 (GSK3) is currently considered to be a
multifunctional serine/threonine kinase involved in awide spectrum
of cellular processes such as glycogen metabolism, cell proliferation,
neuronal function, oncogenesis or embryonic development (for
recent reviews see: Rayasam et al., 2009; Wildburger and Laezza,
2012). Although the protein is expressed in nearly all tissues, its
highest levels and activity are found in the CNS (Leroy and Brion,
1999; Woodgett, 1990). Two distinct, but closely related forms of
GSK3, GSK3a and GSK3b, have been identiﬁed. GSK3 is constitutively
active in resting cells and its activity can be inhibited by phosphory-
lationat serine residues (Ser21 forGSK3a andSer9 forGSK3b) on their
N-terminal domain. By controlling the phosphorylation of these
residues, neurons regulate GSK3 activity (for review see Doble and
Woodgett, 2003). In animal models, the overexpression of GSK-3 in-
duces increased vulnerability to mood-related behavioral distur-
bances and impaired socialization behavior (Mines et al., 2010; Polter
et al., 2010). Furthermore, in clinical studies changes in theexpression
and activity of GSK-3 are found in schizophrenia (Emamian, 2012;
Jope, 2003; Kozlovsky et al., 2001, 2002; Lovestone et al., 2007),
mood disorders (Eldar-Finkelman, 2002; Jope, 2011), addictive be-
haviors (Miller et al., 2009, 2010) and Alzheimer's disease
(Balaramanetal., 2006; Hooper et al., 2008; Kremer et al., 2011).
Recently, the role of GSK3b has emerged in the pathogenesis of pain
(Maixner et al., 2014).
Despite the pleiotropic effects of GSK3, or probably because of
them, many of their molecular targets in the CNS have not yet been
identiﬁed. Lately, GSK-3 has been proposed as a key element in
plasticity at excitatory and inhibitory synapses in the CNS (Bradley
et al., 2012). The molecular mechanisms underlying, at least
partially, the role of GSK-3 in synaptic plasticity is through the
regulation of NMDA and AMPA receptors endocytosis (Bradley
et al., 2012; Chen et al., 2007; Wei et al., 2010).
Given the essential role of plasma membrane trafﬁcking to
control GlyTs activity in excitatory and inhibitory synapsis and the
fact that GSK3 and glycine transporters share implication in some
CNS disorders such as, neuropathic pain, schizophrenia and alcohol
dependence, in this work we have investigated whether GSK3 isinvolved in the modulation of these transporters. Our results pro-
vide evidence of a differential regulation of GlyT1 and GlyT2 by
GSK3b in heterologous and neuronal cells.
2. Materials and methods
2.1. Materials
Wistar rats were bred at the Centro de Biología Molecular Severo Ochoa
(Madrid, Spain). The experiments were performed in accordance with the Royal
Decree 1201/2005 of the Spanish Ministry of Presidency for the protection of ani-
mals used in scientiﬁc research.
[3H]Glycine (PERKIN ELMER) protein standards for sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (Precision Plus Standards) (Bio-Rad), and the
Enhanced Chemiluminescence (ECL) Western blotting detection reagents were ob-
tained from Amersham. GlyT2 inhibitor ALX-1393 O-[(2-Benzyloxyphenyl-3-
ﬂurophenyl) methyl]-L-serine was purchased from Sigma. NFPS (ALX-5407) hydro-
chloride, N-[3-(40-Fluorophenyl)-3-(40-phenylphenoxy) propyl]sarcosine hydro-
chloride was obtained from Axon Medchem. True-Fect-LipoTM was from United
Biosystems (Rockville, MD), EZ-Link SulfoeNHSeSSBiotin was from Pierce. pcDNA3
plasmid was purchased from Invitrogen, the Expand High Fidelity PCR system (Taq
polymerase) and all restriction enzymes were obtained from Roche Applied Science.
The pGEM-T easy cloning vector was purchased from Promega (Madison, WI) and
the oligonucleotides usedwere synthesized by Sigma. The QuikChange Site-Directed
Mutagenesis kit was from Stratagene (La Jolla, CA), nitrocellulose sheets were from
Bio-Rad and fetal calf serum was supplied by Invitrogen.
Rat antibody against GlyT2 and rabbit antibody against GlyT1 have been pre-
viously characterized (Zafra et al., 1995). Antibody against GSK3b were from BD
Transduction Laboratories. Anti-rabbit and anti-rat coupled to AlexaFluor® 555
ﬂuorophore for GlyT1 and GlyT2 and anti-mouse antibody coupled to AlexaFluor®
488 for GSK3b secondary antibodies were used.
All other chemicals were obtained from Sigma.
2.2. Cell growth and transfection
COS-7 cells (American Type Culture Collection) were grown in high glucose
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with 10% fetal bovine
serum at 37 C in an atmosphere of 5% CO2. Transient expression in COS-7 cells was
achieved using TrueFect-Lipo, according to themanufacturers' instructions. The cells
were incubated for 48 h at 37 C and then analyzed biochemically or by immuno-
ﬂuorescence and/or in transport assays.
2.3. Plasmid constructs
GSK3 plasmids: prCMVGSK3b and prCMV K85R GSK3b (DN GSK3b) were kindly
provided by Dr Felix Hernandez (Centro de Biología Molecular Severo Ochoa, Uni-
versidad Autonoma de Madrid, Spain). GlyT1 and GlyT2 cDNAs were subcloned into
pcDNA3, as described (Smith et al., 1992; Liu et al., 1993).
For electrophysiological recordings, the cDNAs for GlyT1, GlyT2, wt GSK3b, and
DN GSK3bwere subcloned into the vector pSP64T, which contains the 5-and 3-UTRs
of the Xenopus laevis globin gene (provided by Dr Carmen Montiel, Universidad
Autonoma de Madrid). All constructs and mutants were conﬁrmed by sequencing.
2.4. Expression in Xenopus oocytes
The cDNAs cloned into pSP64T were linearized with XbaI (GSK3) or SalI (GlyT2
and GlyT1) and the cRNAs were transcribed with SP6 polymerase and capped with
5,7-methylguanosine using the mMESSAGE mMACHINE SP6 RNA kit (Ambion Inc.).
X. laevis frogs were obtained from Xenopus Express (France) and oocytes were
harvested from X. laevis anesthetized in 0.1% (w/v) Tricaine methanesulfonate so-
lution in tap water. All these procedures were performed in accordance with the
Spanish and European guidelines for the prevention of cruelty to animals. The
follicular membrane was removed by incubation in a medium (90 mM NaCl, 1 mM
KCl,1 mMMgCl2, 5 mMHEPES (pH 7.4) containing 300 units/ml collagenase (Type 1;
Sigma) for 1 h. cRNAs encoding either GlyT1 or GlyT1:GSK3b, GlyT1:GSK3b DN or
GlyT2 or GlyT2:GSK3b, GlyT2:GSK3b DN (50 ng) were injected into defolliculated
stage V and VI X. laevis oocytes. The oocytes were maintained in Barth's medium
(88mMNaCl,1mMKCl, 0.33mMCa(NO3)2, 0.41mMCaCl2, 0.82mMMgSO4, 2.4mM
NaHCO3, 10 mM HEPES (pH7.4) and transport or electrophysiological experiments
were carried out 5 days later.
2.5. Two-microelectrode voltage clamp recordings of Xenopus oocytes
Electrophysiological recordings were obtained after incubating the injected
oocytes at 18 C in standard oocyte solution (100 mM NaCl, 2 mM KCl, 1 mM
CaCl2, 1 mM MgCl2, 10 mM HEPES, pH adjusted to 7.5 with HCl). A two-electrode
voltage clamp was used to measure and control the membrane potential and to
monitor the capacitative currents using Axoclamp 900A (Axon Instruments). The
two electrode signals were digitized by a Digidata 1440A (Axon Instruments) and
both instruments were controlled by the pCLAMP software (Axon Instruments).
The results were analyzed by Clampﬁt 10.2 software (Axon Instruments). The
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micropipettes ﬁlled with 3 M KCl (resistance varied between 0.5 and 2 MU).
Oocytes were held at 40 mV and currents were subjected to low pass ﬁltering at
100 Hz.
2.6. Neuron-enriched brainstem primary cultures
Brainstem primary cultures were performed as described (Kaech and Banker,
2006) with modiﬁcations. Brainstems and spinal cords from fetuses from animals
16 days post-conception were isolated in Hanks balanced salt solution (Invi-
trogen) and dissociated with 0.25% Tripsin (Invitrogen) and 4 mg/ml DNAase
(Sigma). Cells were incubated for 4 h in plating buffer (Dulbecco's Modiﬁed Eagle
Medium, Invitrogen, containing 10% fetal calf serum and supplemented with
10 mM glucose, 10 mM sodium pyruvate, 0.5 mM glutamine, 0.05 mg/ml
gentamicin, 0.01% streptomycin, 100 m-units/ml penicillin G) and buffer was
then replaced by culture medium (Neurobasal/B27 50:1 by vol, Invitrogen, con-
taining 0.5 mM glutamine). At 2 days in vitro (DIV) cytosine arabinoside (AraC)
was added to a 10 mM ﬁnal concentration and was progressively diluted with
fresh medium added every 5 days until cultures were used (12e15 DIV). Cells
were plated on poly-lysine (13 mg/ml)-coated 24-well-plates at a density of
200,000 cells/well for transport assays.
2.7. Immunoﬂuorescence of primary neurons from rat brainstem and spinal cord
Primary neurons were analyzed by immunoﬂuorescence as reported previously
(de Juan-Sanz et al., 2013b). The primary antibodies used in this work were incu-
bated overnight at 4 C using the following dilutions: GlyT2 (1:500), GlyT1 (1:2000),
GSK3b (1:1000). The cells were visualized by confocal microscopy on an inverted
microscope AXIOVERT200 (Zeiss).
2.8. Electrophoresis and immunoblotting
SDS-PAGE was performed on 10% polyacrylamide gels in the presence of 2-
mercaptoethanol. After electrophoresis, the protein samples were transferred to
nitrocellulose membranes in a semidry electroblotting system at 1.2 mA/cm2 for 2 h
(LKB) using a transfer buffer containing 192 mM glycine and 25 mM TriseHCl (pHGlyT2 GlyT2:GSK3β GlyT2:DN 
GlyT1 GlyT1:GSK3β GlyT1:DN G
A
B
1 mM gly1 mM gly 1 mM gly
1 mM gl1 mM gly1 mM gly
25 nA
10 s
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10 s
Fig. 1. Effect of GSK3b on glycine transport-associated currents by GlyT1 and GlyT2. A, B, Inw
equal quantities of GlyT1 or GlyT2 cRNA plus GSK3b or DN GSK3b cRNA. Histograms represe
subtracting the currents measured in control oocytes injected with water (n 5e10 oocytes
statistically signiﬁcantly different (p < 0.05; ANOVA with Tukey's post-hoc test) from the c8.3). Nonspeciﬁc binding to the membrane was blocked by incubating the ﬁlter with
5% non-fat milk protein in 10 mM TriseHCl (pH 7.5), 150 mM NaCl for 4 h at 25 C.
Themembranewas then probed overnight at 4 Cwith the diluted primary antibody
which was detected after washing with an IgG peroxidase-linked secondary anti-
body. The labeled bands were visualized by ECL and quantiﬁed by densitometry on a
GS-710 calibrated imaging densitometer from Bio-Rad with Quantity One software
by using ﬁlm exposures in the linear range.
2.9. Transport assays
Glycine transport assays-uptake assays in COS-7 cells and brainstem primary
neuronal cultures were performed at 37 C in PBS as previously described (Fornes
et al., 2008) with modiﬁcations. For GlyT1 activity determination, uptake solution
contained 2 mCi/ml [3H]glycine (1.6 TBq/mmol; NEN Life Science Products), cold
glycine (10 mM ﬁnal concentration) plus 200 nM ALX-1393 to inhibit glycine
transport by GlyT2 with or without the speciﬁc GlyT1 inhibitor NFPS (5 mM) to
measure background glycine accumulation. For GlyT2 activity determination, uptake
solution contained the radioactive substrate plus 5 mM NFPS to inhibit glycine
transport by GlyT1 with or without the speciﬁc GlyT2 inhibitor ALX-1393 (200 nM).
After 10 min incubation, aliquots were obtained for scintillation counting and pro-
tein quantiﬁcation (Bradford method).
2.10. Protein determination
Protein concentrations were determined with the Bio-Rad Protein Determina-
tion kit using bovine serum albumin (BSA) as the standard.
2.11. Cell surface biotinylation
COS-7 cells were plated at 70% conﬂuence in 60 mm cell culture plates and
transfected as indicated above. After 2 days, the cells were washed with ice-cold PBS
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO47H2O, 1.4 mM KH2PO4, pH 7.3) and the
cell surface proteins were labeled for 20 min at 4 C by incubating them in a 1 ml
solution containing the non-permeable SulfoeNHSeSS-Biotin reagent (1 mg/ml in
PBS). The cells were thenwashed with 2 ml of PBS plus 100 mM lysine for 20 min to
quench the reagent. After three additional washes with PBS, the cells were lysed forGSK3β
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E. Jimenez et al. / Neuropharmacology 89 (2015) 245e25424830 min in 1 ml of lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM HEPES-Tris, 0.25%
sodium deoxycholate, 1% Triton X-100, 0.1% SDS, pH 7.4), and the lysate was cleared
by centrifugation at 14,000 g for 10 min. The biotinylated proteins were ﬁnally
recovered by incubating the cleared lysate for 2 h at RT with streptavidin-agarose
beads. After washing the beads three times with 1 ml of the lysis buffer, the pro-
tein bound to the beads was eluted in 2  Laemmli sample buffer, separated by SDS-
PAGE, and analyzed in Western blots. Biotinylated GlyT1 and GlyT2 were revealed
with its correspondent primary antibodies.
For primary neuron cultures, biotinylation was performed as described previ-
ously (Jimenez et al., 2011).
2.12. Metabolic labeling and immunoprecipitation
COS-7 cells were plated on p35 dishes and transfected with True-Fect-LipoTM
according to the manufacturer's instructions. Two days later, the cells were incu-
bated in phosphate-free DMEM for 2 h with TDZD-8 (10 mM) or vehicle and then
metabolically labeled with 0.03 mCi/ml 32P-labeled inorganic phosphate (H3PO4)
with TDZD-8 (10 mM) or vehicle. After labeling for 3.5 h, the cells were rinsed with
Tris-buffered saline solution, and harvested in immunoprecipitation lysis buffer
(50 mM TriseHCl, (pH 8.0), 150 mM NaCl, 1% Nonidet-P40, 0.1% SDS, 0.5% sodium
deoxycholate, 2 mM EDTA, 50 mM NaF, 0.2 mM NaVO3). After incubation for 30 min
at 4 C, cell debris was removed by centrifugation at 12,000 g for 10 min, and the
supernatant was used for immunoprecipitation. The immunoprecipitated material
was resolved by electrophoresis as described below and, after drying, the gels were
submitted to autoradiography.
2.13. Immunoprecipitation
Transiently transfected cells were solubilized in radioimmune precipitation
assay buffer (50 mM TriseHCl, pH 7.5), 1% Nonidet P-40, 0.5% sodium deoxycholate,
150 mM NaCl, 1 mM EGTA, 2 mM EDTA, 0.1 mM DTT. The solubilized material was
centrifuged at 12,000 g for 20 min, and the supernatant was incubated overnight at
4 C with the desired antibodies (2 mg/ml). Subsequently, 40 ml of protein A cross-
linked or protein G cross-linked to agarose beads (Sigma) was added, and the0
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Fig. 2. Effect of GSK3b on GlyT1 and GlyT2 activity in COS cells A, C, [3H]Glycine uptake was
(B) and pcDNA, GSK3b or DN GSK3b. Histograms represent the mean ± SEM (error bars) o
0.9 nmol glycine/mg protein/10 min, respectively. B, D, GlyT1 and GlyT2 immunoblotting of
four independent experiments is displayed. (*p < 0.05, **p < 0.01, statistically signiﬁcantly
pcDNA).mixturewas incubated for 1 h at 4 Cwith constant rotation. The beads werewashed
ﬁve times with ice-cold lysis buffer before adding SDS-PAGE sample buffer to each
sample. The bound proteins were dissociated from the beads by heating at 92 C for
3 min before they were resolved on 10% gels by SDS-PAGE as described below.
2.14. Statistics
Data are provided as means ± SEM, n represents the number of independent
experiments. In order to test the normality of data distribution we used the Kol-
mogoroveSmirnov test obtaining a p value >0.05. All data were tested for signiﬁ-
cance using ANOVA, as applicable and only results with p < 0.05 were considered
statistically signiﬁcant.3. Results
3.1. GSK3b differentially modulates GlyT1 and GlyT2 activity in
Xenopus oocytes and COS-7 cells
Glycinergic neurotransmission is controlled efﬁciently by the
coordinated operation of glycine transporters (GlyTs) that are
presumably regulated by diverse neuronal and glial signaling
pathways. As GSK3b is a central kinase regulating many aspects of
brain physiology, from cell metabolism to cell differentiation, we
decided to investigate the possible functional modulation between
the GSK3b signaling pathway and the glycine transporters GlyT1
and GlyT2.
In order to elucidate the effect of GSK3b on the transport activity
of GlyTs we used X. laevis oocytes and COS-7 cells as heterologous
expression systems. Firstly, we co-expressed either GlyT1 or GlyT2+       
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glycine/mg prot/min and Km in mM. The results represent the means ± SEM of three
triplicate determinations (*, statistically signiﬁcantly different (p < 0.05; ANOVA with
Tukey's post-hoc test) by comparing with GlyT1/GlyT2 plus pcDNA).
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in Xenopus oocytes by injecting the respective encoding cRNAs. The
ionic currents associated with the glycine transport were measured
four days after injection.
Electrogenic glycine transport was minimal in non-injected or
water-injected oocytes (not shown) indicating the absence of basal
glycine-induced currents in the control oocytes. In voltage-clamped
oocytes expressing GlyT1 or GlyT2, glycine (1 mM) induced an in-
ward current (Ig) reﬂecting electrogenic entry of Naþ associated to
the glycine transport (Fig 1A, B). The co-expression of GSK3b caused
a 42 ± 13% reduction in the transport current mediated by GlyT1
and by contrast, a 46 ± 24% increase in the transport currents by
GlyT2. Consistently, these changes were not seen when the trans-
porters were co-expressed with a catalytically inactive form
(dominant negative) of GSK3b, as the current intensity by GlyT1
was 84 ± 33% and by GlyT2 was 102 ± 14% by comparing with the
control (Fig. 1A, B).
These results were further conﬁrmed in the COS-7 mammalian
cell expression system. In agreement with the voltage clamp
measurements, co-expression of GSK3b with glycine transporters
resulted in a stimulation or inhibition of glycine transport by GlyT2
(211 ± 30%) or by GlyT1 (71 ± 15%), respectively. This differential
effect also disappeared when the dominant negative form of GSK3b
was over-expressed (GlyT2 activity was 141 ± 25% and GlyT1 ac-
tivity was 106 ± 20% respect to the control) (Fig. 2). To rule out
unspeciﬁc effects due to different levels of expressed transporters,
the total protein from different experiments was quantiﬁed by
densitometry (representative western blots are shown in Fig. 2B,
D). No signiﬁcant variations in the expression levels of GlyT1 and
GlyT2 (Fig 2B, D) conﬁrm that observed functional changes (Fig. 2A
and C) are by GSK3b and DN GSK3b.
3.2. Kinetic parameters of GlyT1 and GlyT2 are modiﬁed by GSK3b
overexpression
Kinetic analysis of [3H]glycine transport by GlyT1 and GlyT2 in
COS-7 cells showed that in each case, the maximum rate of trans-
port (Vmax) was mainly affected by GSK3bwith mild changes in the
Km. A decrease in the GlyT1 Vmax from 173.1 ± 63.3 nmol gly/
mg protein/10min to 31.7 ± 2.1 nmol gly/mg protein/10 min, and an
increase in the GlyT2 Vmax from 36.5 ± 7.4 nmol gly/mg protein/
10 min to 132.0 ± 2.1 nmol gly/mg protein/10 min was observed.
This modiﬁcation was not produced when the negative dominant
of GSK3b is co-expressed (Fig. 3).
3.3. GSK3b alters GlyT1 and GlyT2 plasma membrane expression
To test the possibility that the observed changes in Vmax were
due to variations in the plasma membrane expression of glycine
transporters, cell surface proteins were labeled with the non-
permeant reagent sulfoeNHSebiotin, isolated with streptavidine-
agarose beads, and quantiﬁed by immunoblotting. Consistent
with the functional results, Fig. 4 shows a decrease of 26 ± 4% of
GlyT1 plasma membrane level and an increase of 339 ± 12% of
GlyT2 surface amount, upon co-expression with GSK3b. These
changes were not observed in the presence of the dominant
negative form of GSK3b.
3.4. GSK3b inhibitors abolish the kinase modulation of the glycine
transporters
As GSK3b presents a high activity in basal situation, and
signaling pathways often operate through the inhibition of GSK3b
activity (Doble and Woodgett, 2003), we used GSK3b inhibitors to
verify the potential involvement of GSK3b in the GlyT1 and GlyT2modulation. Despite its relative speciﬁcity, lithium is one of the best
characterized inhibitors of GSK3b (Klein and Melton, 1996; Ryves
and Harwood, 2001). Pretreatment of COS-7 cells co-expressing
GSK3b and GlyT1, or GlyT2, with 5 mM lithium chloride for 3 h,
prevented the high stimulation of GlyT2 (from 253 ± 12% of control
to 84 ± 6%) and the inhibition of GlyT1 (from 86 ± 3, 5% of control to
102 ± 6%) exerted by GSK3b. Furthermore, similar results were
obtained when cells were preincubated with 10 mM TDZD-8, a
highly speciﬁc non-ATP-competitive GSK3 inhibitor (GlyT2:GSK3b
from 253 ± 12% of control to 81 ± 8% and GlyT1:GSK3b from
86 ± 3.5% of control to 107± 6%) (Fig. 5A, B). The dramatic change in
the GlyT2 activity in response to inhibitors and the marginal effect
on GlyT1 activity are consistent with the larger effect of GSK3b on
GlyT2 regarding GlyT1. Therefore, the reversal of inhibition is more
evident in the case of GlyT2.
3.5. Effect of GSK3b overexpression on GlyT1 and GlyT2
phosphorylation
We studied the possible phosphorylation of these transporters
by GSK3b. COS-7 cells transfected with glycine transporters in the
presence or absence of GSK3b or DN GSK3b were metabolically
labeled with [32P] Pi and immunoprecipitated with anti-GlyT1 and
anti-GlyT2 antibodies. Finally, the immunoprecipitated material
was analyzed by SDS-PAGE and autoradiography. The results
showed that under basal conditions there was a weak incorpora-
tion of 32P into lanes transfected either with GlyT1 (Fig. 6A) or
E. Jimenez et al. / Neuropharmacology 89 (2015) 245e254250GlyT2 (Fig. 6B), but not in the control (transfected with GSK3b plus
cDNA), suggesting that the radioactivity was basally incorporated
into the expressed transporter (Fig. 6, left panels). GSK3b over-
expression increased the 32Pi incorporation into GlyT1 protein and
decreased that of GlyT2. The co-expression with the dominant
negative form of GSK3b suppressed these alterations in the phos-
phorylation status of both transporters. The differences in labeling
were not due to any differences in protein expression as evidenced
when the gels were rehydrated, immunoblotted, and probed with
anti-GlyT1 and anti-GlyT2 antibodies to visualize the amount of
expressed transporter (Fig. 6, left panels). Comparable immunore-
activity was observed in the different extracts independent of the
construct transfected. The radioactive bands had a similar pattern
along the lane to that observed for the immunoreactivity, sup-
porting the hypothesis that the phosphorylated protein was itself
the transporter rather than an associated protein coimmunopre-
cipitating with the transporter. The intensity of autoradiographic
bands was quantiﬁed and normalized for protein expression (Fig. 6,
right panels). Together, these assays indicated that there is differ-
ential regulation of GSK3b in the activity, plasma membrane
expression, and phosphorylation status of the transporters.GlyT1:pcDNA      GlyT1:GSK3β   GlyT1:DN GSK3β 
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Fig. 4. Cell surface expression level of glycine transporters is modiﬁed by GSK3b. A, B,
biotinylation as described in the Materials and methods. In A, and B, representative Weste
non-biotinylated proteins [NB] were subjected to GlyT1 and GlyT2 detection with speciﬁ
statistically signiﬁcantly different, p < 0.05; ANOVA with Tukey's post-hoc test by compari3.6. Pharmacological inhibition of GSK3b affects glycine
transporters in neuron primary cultures of brainstem and spinal
cord
To obtain more insights into the GSK3b regulation we
determined whether endogenously expressed GlyT1 and GlyT2
were functionally modulated through GSK3b as in heterologous
systems. We examined the effect of the kinase inhibitors in
primary neuronal cultures from the rat brainstem and spinal
cord (E16 embryos) where the glycine transporters and GSK3b
co-localized in the same cell (Fig. S1). Cells were treated with
lithium chloride and with the speciﬁc GSK3b inhibitor TDZD-8
(10 mM). Both compounds showed a consistent stimulating ef-
fect on glycine transport mediated by GlyT1, while the GlyT2
activity was clearly inhibited (Fig. 7A). The effect was observed
after 1 h of treatment and continued for approximately 6 h (data
not shown). Furthermore, the cell surface proteins labeled with
the non-permeant reagent sulfoeNHSebiotin after treatment,
consistently showed a decrease of GlyT2 protein and, by
contrast, an increase in the amount of GlyT1 at the plasma
membrane (Fig. 7).Gl
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E. Jimenez et al. / Neuropharmacology 89 (2015) 245e254 251Altogether, Xenopus oocytes, COS-7 cells and neuronal cultures
results suggest that GSK3b exerts a down- and up-regulation of
each transporter, which consequently modulates the glycinergic
neurotransmission.
4. Discussion
The present study reveals a completely novel function of GSK3b,
the differential modulation of the Naþ-coupled glycine transporters
GlyT1 and GlyT2. Considering that the function of these proteins is
critical for the proper functioning of glycinergic and the NMDA-
mediated glutamatergic synapses, the results of this work in-
crease the knowledge of the regulatory mechanisms of excitatory
and inhibitory neurotransmission in the CNS with a potential
pathophysiological impact.
In this work we have shown that the co-expression of GSK3b
with GlyT1 or GlyT2 leads to a down- and up-regulation of the
transporter activity, respectively, in two different heterologousvehicle LiCl TDZD-8
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Fig. 5. GSK3 inhibitors reverse the GSK3b effects on glycine transporters. A, COS-7 cells
expressing GlyT1 or coexpressing GlyT1 and GSK3b (A) were incubated with lithium
chloride (5 mM) and TDZD-8 (10 mM) prior to measuring glycine uptake. This was
measured for 10 min at 1 mM [3H]glycine. B, COS-7 cells expressing GlyT2 or coex-
pressing GlyT2 and GSK3b were treated as in A. Histograms represent the mean ± SEM
(error bars) of four experiments. 100% glycine transport by GlyT1 in vehicle, LiCl and
TDZD-8 treatment were 6.5, 6.9 and 5.9 nmol gly/mg protein/10 min, respectively.
100% glycine transport by GlyT2 in vehicle, LiCl and TDZD-8 treatment correspond to
0.8, 0.6 and 0.9 nmol gly/mg protein/10 min, respectively. GlyT1:GSK3b or
GlyT2:GSK3b treatment values were compared with GlyT1:GSK3b or GlyT2:GSK3b
vehicle values by using ANOVA with Tukey's post-hoc test *, statistically signiﬁcantly
different p < 0.05.expression systems, COS-7 cells and X. laevis oocytes. These func-
tional changes are consistent with a decrease and increase of the
GlyT1 and GlyT2 levels at the plasma membrane, respectively. The
speciﬁcity of these changes is supported by the antagonism exerted
by a catalytically inactive form of the kinase and through inhibitors
of GSK3b kinase, such as TDZD-8 and lithium. Additional evidence
of the opposite modulation carried out by the overexpression of
GSK3b on GlyT1 and GlyT2, are provided by the results of the
pharmacological inhibition of GSK3b in neuron primary cultures of
brainstem and spinal cord. Both, the activity and cell surface
expression of the endogenous transporters showed changes as a
result of neuronal kinase inhibition. Altogether, the different
modulation of GlyT1 and GlyT2 exerted by GSK3b in neuronal
cultures and in cells expressing the recombinant proteins indicates
that the observed glycine transport regulation is indeed the
consequence of speciﬁc effects on the transporters.
Glycogen synthase kinase 3 (GSK3b) is highly expressed in the
CNS and is considered to be a multifunctional serine/threonine
kinase involved in neuronal development, mood stabilization, and
neurodegeneration. Recently it has been proposed that GSK3b plays
amajor role in plasticity at excitatory and inhibitory synapses in the
CNS (Bradley et al., 2012). The underlying molecular mechanisms
involved are, at least partially, via the regulation of the function and
trafﬁcking of NMDA and AMPA receptors (Chen et al., 2007; Bradley
et al., 2012; Wei et al., 2010). Data from this work add an additional
control point of glutamatergic neurotransmission by GSK3b.
Considering that GlyT1 is the main regulator of glycine availability
near to NMDA receptors, the modulation of its activity and cell
surface presence by GSK3b could indirectly modulate the NMDAR-
mediated glutamatergic synapses. Moreover, GlyT2 is the main
supplier of glycine for constitutive vesicle reﬁlling through active
reuptake of the neurotransmitter to the terminal. This process is
absolutely crucial to preserve the quantal glycine content inside the
synaptic vesicles and is critical for regulating inhibitory synaptic
strength (Gomeza et al., 2003b; Rousseau et al., 2008; Apostolides
and Trussell, 2013). Therefore, because GlyT2 activity regulates the
glycinergic synaptic strength, the new modulatory mechanism by
GSK3b described here is of great physiological relevance. The re-
sults of this work suggest that constitutively active endogenous
GSK3b is important for stabilizing and/or controlling the expression
of functional GlyTs on the neural cell surface. The data described
here and elsewhere (Chen et al., 2007; Bradley et al., 2012; Wei
et al., 2010) could represent a more general process underlying
CNS synaptic plasticity whereby GSK3b controls neuronal proteins
that are crucial for the proper functioning of inhibitory and excit-
atory fast neurotransmission.
It is interesting to note that GlyT1 and GlyT2 are modulated in
a coordinated and opposite way as that shown in this work by
different mechanisms and situations. An example is the puriner-
gic control of GlyT1 and GlyT2 through P2Y receptors in brainstem
and spinal cord neurons. This mechanism promotes the func-
tioning of inhibitory pathways over the excitatory ones in the
spinal cord which would result in anti-nociception. This has been
interpreted as part of a homeostatic mechanism in pain process-
ing that relies on the control exerted by GlyT1 and GlyT2 in the
balance of the neuronal excitation and inhibition of some
neuronal circuits such as the dorsal spinal cord (Jimenez et al.,
2011). In addition, it has been described that the chronic treat-
ment of a clinically relevant concentration of ethanol evokes
differential adaptive responses on the activity and membrane
expression levels of recombinant GlyT1 and GlyT2 transporters.
These changes are part of the glutamatergic and glycinergic
neurotransmission alterations produced by alcoholic intoxication
and contribute to the depressive effects induced by ethanol in the
CNS (Nu~nez et al., 2000).
E. Jimenez et al. / Neuropharmacology 89 (2015) 245e254252All of the above demonstrates that the physiologic function of
the GlyTs is ﬁnely controlled by different mechanisms and that
these proteins are pharmacologic targets of choice for the treat-
ment of pathologies underlying an imbalance of neuronal excita-
tion and inhibition. A paradigmatic example is schizophrenia
resulting from deﬁcient glutamate signaling via NMDA receptors
(Javitt, 2007; Coyle, 2012). The inhibition of glycine transport by
GlyT1 near to NMDAR is a current pharmacologic strategy
(Kristensen et al., 2011) as evidenced by the numerous synthetic
GlyT1 inhibitors currently in advanced clinical trials. One of these
inhibitors, bitopertin, is currently in Phase III clinical trials (Harvey
and Yee, 2013). Developing a GlyTs based pharmacology is being
considered for future application to pathologies other than
schizophrenia, such as alcohol dependence, neuropathic pain, ep-
ilepsy and mood disorders. Taking into consideration that changes
in the expression and activity of GSK3b have been found in con-
ditions such as schizophrenia (Kozlovsky et al., 2001, 2002; Jope,
2003; Lovestone et al., 2007; Emamian, 2012), mood disorders
(Eldar-Finkelman, 2002; Jope, 2011), and addictive behaviors
(Miller et al., 2009, 2010), the modulation of GlyTs by GSK3b
described in this work could be of great pathophysiological sig-
niﬁcance. Furthermore, a better understanding of the mechanisms
that control the activity of these glycine transporters will help to
elucidate its true value as pharmacologic targets.
We have provided evidence that GSK3b is involved in the
phosphorylation status of GlyT1 and GlyT2. The decrease inA
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Fig. 6. Effect of GSK3b overexpression on GlyT1 and GlyT2 phosphorylation. Left panels.
pCDNA3, GSK3b or DN GSK3b in the combinations indicated. After metabolic labeling with
transporters were immunoprecipitated with anti-GlyT1 or anti-GlyT2 antibodies as descr
subjected to autoradiography. Gels were rehydrated in 50 mM ammonium bicarbonate, and
antiserum. Right panels. Densitometric analysis of 32Pi incorporation measured by autor
average ± SEM of three independent experiments. (*, statistically signiﬁcantly different, p <
Arrow indicates the quantiﬁed band.GlyT2 32Pi incorporation upon co-expression with the kinase
suggests that the modulation could be mediated by other ki-
nases, probably inhibited by GSK3b, or alternatively through the
activation of a phosphatase. By contrast, GlyT1 phosphorylation
status appears to be increased in the presence of GSK3b,
although we could not conclude that is a direct phosphorylation.
These results do not allow conclude that changes in the phos-
phorylation status of GlyTs by overexpression of GSK3 are the
direct cause of the observed alterations in the trafﬁcking of the
transporters. However, the parallels changes in the activity,
plasma membrane expression and phosphorylation of GlyT1 and
GlyT2 seem to be relevant to the mechanism underlying the
regulation by GSK3b.
5. Conclusions
This study describes a novel function of GSK3b, the opposite
modulation of the glycine transporters GlyT1 and GlyT2. GSK3b
induces a decrease in GlyT1 and an increase in GlyT2 levels at the
plasma membrane. These changes are antagonized by a catalyti-
cally inactive form of the kinase and by inhibitors of GSK3b (lithium
chloride and TDZD-8). Therefore, GSK3b function appears to be an
important factor for stabilizing and/or controlling the expression of
functional GlyTs on the neural cell surface.
Our results suggest that constitutively active GSK3b is important
in stabilizing and/or controlling the expression of functional GlyTsGl
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Fig. 7. Effect of endogenous GSK3b inhibition on glycine transporters in primary neuron cultures. A, and B, Primary neuron cultures from brainstem and spinal cord were incubated
at 37 C with lithium chloride (5 mM) and TDZD-8 (10 mM) prior measuring glycine uptake. This was measured as indicated in Fig. 5. Histograms represent the mean ± SEM (error
bars) of four experiments. 100% glycine transport by GlyT1 and GlyT2 correspond to 0.25 and 0.21 nmol glycine/mg protein/10 min, respectively. Values were compared with control
values by using ANOVA with Tukey's post-hoc test, *, statistically signiﬁcantly different p < 0.05. C, and D, after lithium chloride (5 mM) and TDZD-8 (10 mM) treatment, neurons
were subjected to NHS-SS-biotinylation as described in the Materials and Methods section. Representative Western blots are shown. Total proteins, T (6 mg), surface biotinylated
proteins, B (18 mg) and non-biotinylated proteins [NB] were subjected to GlyT1 and GlyT2 detection with speciﬁc antibodies. Densitometric analysis of three independent ex-
periments is displayed. (*, statistically signiﬁcantly different p < 0.05 ANOVA with Tukey's post-hoc test by comparing with control).
E. Jimenez et al. / Neuropharmacology 89 (2015) 245e254 253on the neural cell surface. This could represent a more general
process underlying CNS synaptic plasticity where GSK3b controls
neuronal proteins that are crucial to the proper functioning of
inhibitory and excitatory fast neurotransmission.Acknowledgments
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